Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Endometrial Adenocarcinoma 1Bilateral Breast Carcinoma 1

Interventions

pembrolizumab 524Specimen Handling 383Carboplatin 377Magnetic Resonance Spectroscopy 336Cisplatin 332Nivolumab 308Cyclophosphamide 298Radiotherapy 257Paclitaxel 255Gemcitabine 235Biopsy 235Bevacizumab 218Dexamethasone 169durvalumab 168Oxaliplatin 163Capecitabine 158Rituximab 157Fluorouracil 149venetoclax 147Docetaxel 147Etoposide 142Drug Therapy 142atezolizumab 141Doxorubicin 134Ipilimumab 129Radiosurgery 120Prednisone 120Lenalidomide 119Leucovorin 113fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Epothilones × 1 year × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡